|
1
|
Parkin DM: The global burden of urinary
bladder cancer. Scand J Urol Nephrol. (Suppl): 12–20. 2008.
View Article : Google Scholar
|
|
2
|
Noon AP, Albertsen PC, Thomas F, Rosario
DJ and Catto JW: Competing mortality in patients diagnosed with
bladder cancer: Evidence of undertreatment in the elderly and
female patients. Br J Cancer. 108:1534–1540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zarogoulidis K, Boutsikou E, Zarogoulidis
P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G,
Kanakis I and Karamanos NK: The impact of zoledronic acid therapy
in survival of lung cancer patients with bone metastasis. Int J
Cancer. 125:1705–1709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirata H, Hinoda Y, Ueno K, Shahryari V,
Tabatabai ZL and Dahiya R: MicroRNA-1826 targets VEGFC,
beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.
Carcinogenesis. 33:41–48. 2012. View Article : Google Scholar :
|
|
5
|
Alcaraz A, González-López R, Morote J, de
la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B,
Alvarez-Ossorio JL, Chirivella I, et al: Biochemical markers of
bone turnover and clinical outcome in patients with renal cell and
bladder carcinoma with bone metastases following treatment with
zoledronic acid: The TUGAMO study. Br J Cancer. 109:121–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaghloul MS, Boutrus R, El-Hossieny H,
Kader YA, El-Attar I and Nazmy M: A prospective, randomized,
placebo-controlled trial of zoledronic acid in bony metastatic
bladder cancer. Int J Clin Oncol. 15:382–389. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saad F and Eastham JA: Zoledronic acid use
in patients with bone metastases from renal cell carcinoma or
bladder cancer. Semin Oncol. 37(Suppl 1): S38–S44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gouin F, Ory B, Rédini F and Heymann D:
Zoledronic acid slows down rat primary chondrosarcoma development,
recurrent tumor progression after intralesional curretage and
increases overall survival. Int J Cancer. 119:980–984. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goffinet M, Thoulouzan M, Pradines A,
Lajoie-Mazenc I, Weinbaum C, Faye JC and Séronie-Vivien S:
Zoledronic acid treatment impairs protein geranyl-geranylation for
biological effects in prostatic cells. BMC Cancer. 6:602006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koto K, Murata H, Kimura S, Sawai Y, Horie
N, Matsui T, Ryu K, Ashihara E, Maekawa T, Kubo T, et al:
Zoledronic acid significantly enhances radiation-induced apoptosis
against human fibrosarcoma cells by inhibiting radioadaptive
signaling. Int J Oncol. 42:525–534. 2013.
|
|
11
|
Rowinsky EK, Windle JJ and Von Hoff DD:
Ras protein farne-syltransferase: A strategic target for anticancer
therapeutic development. J Clin Oncol. 17:3631–3652.
1999.PubMed/NCBI
|
|
12
|
Wei J, Zaika E and Zaika A: p53 Family:
Role of protein isoforms in human cancer. J Nucleic Acids.
2012:6873592012. View Article : Google Scholar
|
|
13
|
Stiewe T and Putzer BM: Role of p73 in
malignancy: Tumor suppressor or oncogene? Cell Death Differ.
9:237–245. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lunghi P, Costanzo A, Mazzera L, Rizzoli
V, Levrero M and Bonati A: The p53 family protein p73 provides new
insights into cancer chemosensitivity and targeting. Clin Cancer
Res. 15:6495–6502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomkova K, Belkhiri A, El-Rifai W and
Zaika AI: p73 isoforms can induce T-cell factor-dependent
transcription in gastrointestinal cells. Cancer Res. 64:6390–6393.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zaika AI and El-Rifai W: The role of p53
protein family in gastrointestinal malignancies. Cell Death Differ.
13:935–940. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Conforti F, Yang AL, Agostini M, Rufini A,
Tucci P, Nicklison-Chirou MV, Grespi F, Velletri T, Knight RA,
Melino G, et al: Relative expression of TAp73 and ΔNp73 isoforms.
Aging (Albany NY). 4:202–205. 2012.
|
|
18
|
Rufini A, Agostini M, Grespi F, Tomasini
R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A,
Mak TW, et al: p73 in Cancer. Genes Cancer. 2:491–502. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin D, Cui Z, Kong L, Cheng F, Xu J and
Lan F: p73 participates in WWOX-mediated apoptosis in leukemia
cells. Int J Mol Med. 31:849–854. 2013.PubMed/NCBI
|
|
20
|
Grob TJ, Novak U, Maisse C, Barcaroli D,
Lüthi AU, Pirnia F, Hügli B, Graber HU, De Laurenzi V, Fey MF, et
al: Human delta Np73 regulates a dominant negative feedback loop
for TAp73 and p53. Cell Death Differ. 8:1213–1223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Samudio I, Fiegl M and Andreeff M:
Mitochondrial uncoupling and the Warburg effect: Molecular basis
for the reprogramming of cancer cell metabolism. Cancer Res.
69:2163–2166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jones RG and Thompson CB: Tumor
suppressors and cell metabolism: A recipe for cancer growth. Genes
Dev. 23:537–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang P, Du W, Wang X, Mancuso A, Gao X,
Wu M and Yang X: p53 regulates biosynthesis through direct
inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol.
13:310–316. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Du W, Jiang P, Mancuso A, Stonestrom A,
Brewer MD, Minn AJ, Mak TW, Wu M and Yang X: TAp73 enhances the
pentose phosphate pathway and supports cell proliferation. Nat Cell
Biol. 15:991–1000. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fernandez-Garcia B, Vaqué JP,
Herreros-Villanueva M, Marques-Garcia F, Castrillo F,
Fernandez-Medarde A, León J and Marín MC: p73 cooperates with Ras
in the activation of MAP kinase signaling cascade. Cell Death
Differ. 14:254–265. 2007. View Article : Google Scholar
|
|
27
|
Chang J, Wang W, Zhang H, Hu Y and Yin Z:
Bisphosphonates regulate cell proliferation, apoptosis and
pro-osteoclastic expression in MG-63 human osteosarcoma cells.
Oncol Lett. 4:299–304. 2012.PubMed/NCBI
|
|
28
|
Ohtsuka Y, Manabe A, Kawasaki H, Hasegawa
D, Zaike Y, Watanabe S, Tanizawa T, Nakahata T and Tsuji K:
RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal
proliferation and differentiation of juvenile myelomonocytic
leukemia cells in vitro. Blood. 106:3134–3141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riganti C, Castella B, Kopecka J, Campia
I, Coscia M, Pescarmona G, Bosia A, Ghigo D and Massaia M:
Zoledronic acid restores doxorubicin chemosensitivity and
immunogenic cell death in multidrug-resistant human cancer cells.
PLoS One. 8:e609752013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cairns RA, Harris I, McCracken S and Mak
TW: Cancer cell metabolism. Cold Spring Harb Symp Quant Biol.
76:299–311. 2011. View Article : Google Scholar : PubMed/NCBI
|
